Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has announced Ivor Elrifi as its new CEO, a seasoned expert in intellectual property and business development within the biotech sector. Elrifi’s appointment is expected to bolster the company’s efforts in advancing its leading drug candidate, intranasal foralumab, through critical clinical trials for several neurological diseases. The company emphasizes its focus on addressing unmet medical needs and enhancing shareholder value under Elrifi’s leadership.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
